Please provide your email address to receive an email when new articles are posted on . Poxel SA announced positive results for the phase 2a trial of PXL770 for the treatment of nonalcoholic ...
Betagenon /Balticgruppen Bio AB announces the start of a bridging PK and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator compound O304 STOCKHOLM, Aug. 17, 2020 ...
The New York based biotech company announces launch of Amplifier Therapeutics to develop the clinical stage pan-AMPK activator, ATX-304 NEW YORK, March 14, 2023 /PRNewswire/ -- Cambrian Bio, a ...
The primary objective of the study was to assess the full pharmacokinetic (PK) profile of PXL770 as well as to evaluate safety and tolerability. PXL770 is a first-in-class direct adenosine ...
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 ...
Globally ~40% of type 2 diabetes (T2D) patients develop diabetic kidney disease (DKD), and diabetes is the leading cause of end stage renal disease, requiring dialysis or a kidney transplant. Standard ...
Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate ...
Biolexis Therapeutics Inc. is working on developing orally available, small-molecule AMPK activators that have been found to stimulate AMPK activity as well as dose-dependently enhance glucose uptake ...
Credit: Shutterstock. PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. The Food and Drug Administration (FDA) has granted Fast Track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback